Academic Journal
Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: A randomized controlled trial. Journal of the American Medical Association 2013; 309: 453–460
| العنوان: | Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: A randomized controlled trial. Journal of the American Medical Association 2013; 309: 453–460 |
|---|---|
| المؤلفون: | Kurklinsky, Andrew K, Levy, Michael |
| المصدر: | Vascular Medicine ; volume 18, issue 4, page 234-236 ; ISSN 1358-863X 1477-0377 |
| بيانات النشر: | SAGE Publications |
| سنة النشر: | 2013 |
| الوصف: | Study objective: The objective of the trial was to examine whether ramipril, an angiotensin-converting enzyme (ACE), improves walking distance and health-related quality of life in patients with peripheral artery disease (PAD) associated with claudication. Study population: The study enrolled 212 patients with risk factors and symptoms of PAD treated by conventional therapies at three centers in Australia. All patients had an ankle–brachial index (ABI) of less than 0.90 at rest and intermittent claudication in at least one leg, which were stable for at least 6 preceding months along with the medication regimen. The patients were excluded if blood pressure was not controlled (brachial blood pressure of 160/100 mmHg or greater); if there was current or recent use of either ACE inhibitors or angiotensin II receptor blockers, potassium-sparing diuretics, or potassium supplements; renal failure (serum creatinine level 2.3 mg/dL or greater [200 µmol/L]); renal artery stenosis; previous coronary or peripheral artery revascularizations, recent myocardial infarction and other health conditions other than PAD that could adversely influence walking ability at the time of screening and for 1 year thereafter. Design and methods: This was a randomized, placebo-controlled, triple blinded study of ramipril at the high daily dose (10 mg) for 6 months. Primary outcomes were pain-free and maximum walking times assessed by a standard treadmill exercise test. Secondary outcomes were ABI changes; symptoms and functional status assessed by the Walking Impairment Questionnaire (WIQ) 1 ; health-related quality of life assessed by the Short-Form 36 Health Survey (SF-36) 2 ; and stenosis severity assessed by duplex ultrasound of the lower limb arteries. At baseline and at follow-up, pain-free and maximum walking distances were assessed by the standard constant load treadmill exercise test performed at a speed of 3.2 km/h and a grade of 12%. 3 ABI was calculated in both legs. Duplex ultrasonography was used to determine stenosis in ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1177/1358863x13497529 |
| DOI: | 10.1177/1358863X13497529 |
| الاتاحة: | https://doi.org/10.1177/1358863x13497529 https://journals.sagepub.com/doi/pdf/10.1177/1358863X13497529 https://journals.sagepub.com/doi/full-xml/10.1177/1358863X13497529 |
| Rights: | https://journals.sagepub.com/page/policies/text-and-data-mining-license |
| رقم الانضمام: | edsbas.76D47A0B |
| قاعدة البيانات: | BASE |
| DOI: | 10.1177/1358863x13497529 |
|---|